|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
37.280 -1.000 (-2.612%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Turnover | 6,271,913 | -0.166% | 6,282,354 | 6,689,918 | 6,302,565 | 6,235,531 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (25,222) | -50.295% | (50,744) | (85,212) | (119,450) | (2,396) | |
| Profit / (Loss) on Disposal | (150) | 95.870% | (76) | (328) | (511) | 317 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 28,943 | 117.076% | 13,333 | 37,016 | 37,182 | 5,964 | |
| Profit / (Loss) before Taxation | 1,828,110 | 13.661% | 1,608,394 | 1,423,370 | 1,322,573 | 1,371,166 | |
| Taxation | (276,889) | 9.142% | (253,695) | (249,299) | (205,070) | (191,385) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (270,133) | 47.029% | (183,728) | (39,500) | (99,957) | (117,306) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,281,088 | 9.404% | 1,170,971 | 1,134,570 | 1,017,546 | 1,062,476 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (165,118) | 112.802% | (77,592) | (41,453) | (95,511) | (25,014) |
| Depreciation & Amortisation | 313,375 | -7.779% | 339,809 | 513,207 | 266,864 | 224,033 |
| Directors' Emoluments | 6,503 | -0.245% | 6,519 | 6,213 | 6,228 | 6,340 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| EPS (cts) | 143.000 | 12.598% | 127.000 | 122.000 | 109.000 | 114.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 15.129 | -- | 15.027 | 14.337 | 13.762 | 12.825 |
| Remarks: | Real time quote last updated: 22/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,281,088 |
| %Change | 9.404% |
| EPS / (LPS) | RMB 1.430 |
| NBV Per Share (¥) | RMB 15.129 |